BioGend Therapeutics Co., Ltd. (TPEX: 6733)
Taiwan
· Delayed Price · Currency is TWD 37.30
-0.30 (-0.80%)
Oct 11, 2024, 9:39 AM CST
BioGend Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 133.45 | 109.91 | 31.45 | 9.27 | 1.39 | 1.46 | Upgrade
|
| Revenue Growth (YoY) | 91.07% | 249.51% | 239.26% | 565.40% | -4.65% | - | Upgrade
|
| Cost of Revenue | 25.43 | 20.29 | 8.67 | 6.21 | 0.66 | 1.28 | Upgrade
|
| Gross Profit | 108.02 | 89.62 | 22.78 | 3.06 | 0.73 | 0.19 | Upgrade
|
| Selling, General & Admin | 107.3 | 95.16 | 75.73 | 54.09 | 40.14 | 34.56 | Upgrade
|
| Research & Development | 154.01 | 171 | 166.27 | 113.27 | 94.21 | 132.74 | Upgrade
|
| Operating Expenses | 261.31 | 266.16 | 241.99 | 167.37 | 134.35 | 167.3 | Upgrade
|
| Operating Income | -153.29 | -176.54 | -219.21 | -164.31 | -133.62 | -167.11 | Upgrade
|
| Interest Expense | -0.24 | -0.26 | -0.09 | -0.02 | -0.01 | - | Upgrade
|
| Interest & Investment Income | 7.88 | 6.92 | 4.59 | 2.88 | 2.35 | 3.19 | Upgrade
|
| Earnings From Equity Investments | -1.79 | -0.84 | - | -11.35 | -14.24 | -4.83 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.07 | 0.51 | 0.13 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.53 | 1.46 | 0.74 | 0.87 | 0.27 | 5.85 | Upgrade
|
| EBT Excluding Unusual Items | -145.88 | -169.22 | -213.9 | -171.4 | -145.12 | -162.9 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 26.7 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.48 | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.44 | - | - | Upgrade
|
| Pretax Income | -145.88 | -169.22 | -213.9 | -144.27 | -145.59 | -162.9 | Upgrade
|
| Income Tax Expense | -8.3 | -8.3 | -8.4 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -137.58 | -160.92 | -205.5 | -144.27 | -145.59 | -162.9 | Upgrade
|
| Minority Interest in Earnings | 16.66 | 4.59 | 21.04 | 5.78 | - | - | Upgrade
|
| Net Income | -120.92 | -156.33 | -184.46 | -138.49 | -145.59 | -162.9 | Upgrade
|
| Net Income to Common | -120.92 | -156.33 | -184.46 | -138.49 | -145.59 | -162.9 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 120 | 103 | 101 | 87 | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 120 | 103 | 101 | 87 | 81 | Upgrade
|
| Shares Change (YoY) | 11.65% | 16.69% | 1.77% | 15.90% | 7.56% | 33.88% | Upgrade
|
| EPS (Basic) | -0.98 | -1.30 | -1.79 | -1.37 | -1.67 | -2.01 | Upgrade
|
| EPS (Diluted) | -0.98 | -1.30 | -1.79 | -1.37 | -1.67 | -2.01 | Upgrade
|
| Free Cash Flow | -133.72 | -164.76 | -186.96 | -137.47 | -117.33 | -147.53 | Upgrade
|
| Free Cash Flow Per Share | -1.09 | -1.37 | -1.81 | -1.36 | -1.34 | -1.82 | Upgrade
|
| Gross Margin | 80.95% | 81.54% | 72.44% | 33.00% | 52.48% | 12.66% | Upgrade
|
| Operating Margin | -114.87% | -160.63% | -697.11% | -1772.67% | -9591.89% | -11438.26% | Upgrade
|
| Profit Margin | -90.61% | -142.23% | -586.58% | -1494.07% | -10451.83% | -11150.10% | Upgrade
|
| Free Cash Flow Margin | -100.21% | -149.91% | -594.54% | -1483.13% | -8422.90% | -10098.15% | Upgrade
|
| EBITDA | -102.96 | -125.21 | -170.87 | -137.9 | -114.42 | -149.01 | Upgrade
|
| EBITDA Margin | -77.15% | -113.92% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 50.33 | 51.33 | 48.35 | 26.41 | 19.19 | 18.11 | Upgrade
|
| EBIT | -153.29 | -176.54 | -219.21 | -164.31 | -133.62 | -167.11 | Upgrade
|
| EBIT Margin | -114.87% | -160.63% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.